AMGEN INC.

(AMGN)
  Rapport
Geschatte realtime Cboe BZX  -  19:14 30-06-2022
243.13 USD   -0.94%
15/06Amgen Inc. Herbevestigt inkomstenrichtsnoer voor het jaar 2022
CI
06/06Amgen zegt dat FDA Riabni goedkeurt voor de behandeling van reumatoïde artritis
MT
06/06Amgen Inc. Kondigt aan dat U.S. Food and Drug Administration RIABNI goedkeurt
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op AMGEN INC.
15/06Amgen Inc. Reaffirms Revenue Guidance for the Year 2022
15/06TRANSCRIPT : Amgen Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference..
10/06Amgen announces webcast of goldman sachs 43rd annual healthcare conference
09/06BEHIND ONE BIOTECH'S WATER CONSERVAT : Saving Every Drop
08/06TRANSCRIPT : Amgen Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-20..
07/06Amgen - FDA APPROVES RIABNI (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN (RITUXIMAB), FOR ..
06/06NEW BPCIA COMPLAINT : Genentech Files Suit Against Tanvex Regarding Its Proposed Herceptin..
06/06Amgen Says FDA Approves Riabni to Treat Rheumatoid Arthritis
06/06FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXANģ (RITUXIMAB), FOR ..
06/06Amgen Inc. Announces U.S. Food and Drug Administration Approves RIABNI
06/06AMGEN : FDA OK's Riabni Biosimilar to Rituxan in Rheumatoid Arthritis
05/06Amgen drug extends survival in some inoperable colon cancers
05/06Amgen and Takeda Pharmaceutical Company Announces New Data from the Phase 3 Paradigm Cl..
03/06Amgen announces webcast of 2022 jefferies healthcare conference
03/06Regeneron Files Antitrust Lawsuit Accusing Amgen Of Engaging In A Persistent Exclusiona..
02/06AMGEN : Statement on Russia/Ukraine
31/05Amgen Says it Sees Positive Topline Results From Phase 2 Trial of Olpasiran to Reduce L..
31/05AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS W..
31/05Amgen Announces Positive Topline Phase 2 Data for Investigational Olpasiran in Adults w..
31/05Amgen Reports Positive Phase 2 Study of Olpasiran in Lipoprotein(a)
27/05Amneal Gets FDA OK for Biosimilar to Amgen's Neulasta
27/05Mirati lung cancer data disappoint, shares fall 21%
26/05Mirati drug shrinks tumors in 44% of advanced lung cancer patients
23/05Biden comments reassure investors
23/05USA-Les valeurs à suivre à Wall Street (actualisé)
23/05ANALYST RECOMMANDATIONS : AbbVie, Amgen, Caterpillar, HP, Nike...
18/05AMGEN INC : Submission of Matters to a Vote of Security Holders (form 8-K)
13/05Avantor Names Jonathan Peacock Chairman
12/05Amgen and lance bass partner to encourage people to do a 'double take' to recognize the..
12/05BridgeBio Inks BBP-398 License With Bristol Myers
11/05TRANSCRIPT : Amgen Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-202..
11/05INSIDER SELL : Amgen
10/05Pfizer to pay $11.6 bln for Biohaven to tap migraine market
09/05Amgen announces webcast of 2022 bank of america healthcare conference
06/05Amgen announces webcast of 2022 bank of america healthcare conference
04/05Will The Supreme Court Take The Bait? CVSG Issued And Other Updates In The Amgen v. San..
04/05BeiGene Says China Gives Conditional Approval to Blincyto Injection for Pediatric Acute..
02/05Amgen releases annual environmental, social & governance report
28/04Wall Street ends sharply higher, lifted by Meta and Apple
28/04MÄRKTE USA/Steil aufwärts - Meta befeuert Tech-Fantasie
28/04MÄRKTE USA/Etwas fester - Meta steigen zweistellig
28/04Borsa Usa mista tra solida trimestrale di Meta e rallentamento Pil
28/04MÄRKTE USA/Fester - Gute Quartalszahlen lassen schwaches BIP verblassen
28/04MÄRKTE USA/Fest - Meta stimmt optimisch für Technologiesektor
28/04AKTIEN NEW YORK AUSBLICK : Gewinne - Meta treibt Erholung im Tech-Sektor an
28/04Amgen enttäuscht mit unveränderter Prognose und Steuerrückforderung
28/04MARKT USA/Fest - Meta-Zahlen stimmen optimisch für Technologiesektor
28/04Tranche Update on Amgen Inc.'s Equity Buyback Plan announced on April 21, 2011.
28/04AMGEN INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF ..
28/04Molecular Partners to Regain Global Rights To MP0310
28/04BOLSA DE MADRID : La venganza de Meta
28/04La vengeance pour Meta, la dépréciation pour TotalEnergies
28/04EN DIRECT DES MARCHES : Capgemini, TotalEnergies, Thales, Soitec, Albioma, Nokia, Meta, Pa..
28/04AMGEN : REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS - Form 8-K
27/04US Stocks Inch Higher With Nasdaq Closing Flat Ahead of Meta, Qualcomm Results
27/04Amgen enttäuscht mit unveränderter Prognose
27/04TRANSCRIPT : Amgen Inc., Q1 2022 Earnings Call, Apr 27, 2022
27/04Amgen says IRS seeks billions in back taxes, shares fall 6%
27/04US Stocks Close Higher on Wednesday, With Nasdaq Ending Marginally Lower Ahead of Quart..
27/04AMGEN : Q1 Earnings Snapshot
27/04Amgen Inc. Provides Earnings Guidance for the Year 2022
27/04Amgen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
27/04Amgen Q1 Non-GAAP EPS, Revenue Higher; Releases 2022 Guidance
27/04Big Biotech Firms Have Several Catalysts Lined Up, UBS Says
27/04Earnings Flash (AMGN) AMGEN Reports Q1 Revenue $6.24B, vs. Street Est of $6.115B
27/04Earnings Flash (AMGN) AMGEN Posts Q1 EPS $4.25, vs. Street Est of $4.13
27/04Amgen 1Q Revenue Beats Expectations, Profit Declines
27/04EARNINGS REACTION HISTORY : Amgen Inc, 70.0% Follow-Through Indicator, 3.7% Sensitive
27/04AKTIEN SCHWEIZ SCHLUSS : Auf Erholungskurs dank Schwergewichten
27/04Amgen Says Two Studies of Repatha Show Decrease in Cholesterol Levels
27/04Wall Street Set to Open Higher; Nasdaq Lags After Lackluster Alphabet Earnings
27/04Amgen announces results from two open label extension studies of repathaģ (evolocumab)
27/04Amgen Announces Top-Line Results from Two Repathaģ Open Label Extension Studies to the ..
27/04Top Premarket Decliners
27/04BOLSA DE MADRID : La moral está por los suelos
1  2  3  4  5  6  7  8  9  10Volgende
OfficiŽle publicaties